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Aim: The aim of this study was to determine the incidence of TNBC in Kuwait, to analyze
the clinicopathologic features and prognosis of this type of breast cancer, and compare it
with  reports from other regions of the world.
Background: Triple negative breast cancer (TNBC) is deﬁned as a subtype that is negative for
estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2
(HER2). There is a growing evidence of the heterogeneity of such entity on the molecular
level that may cause discrete outcomes.
Methods: We  analyzed the clinicopathologic features of 363 TNBC cases which were diag-
nosed in Kuwait from July 1999 to June 2009. The disease-free survival (DFS) and overall
survival (OS) were analyzed by Kaplan–Meier method. Comparison was done with reports
from  USA, Europe, Middle and Far East.
Results: Among 2986 patients diagnosed with breast cancer in Kuwait, 363 patients (12.2%)
were TNBC. The median age was 48 years, 57.2% had lymph nodes (LN) metastasis, 56.9%
were of grade III tumor and 41.9% had stage II disease. 81% developed recurrences and 75% of
deaths occurred by 2.5 years after treatment. There is marked variation of clinicopathologic
features according to country of patients’ cohort.
Conclusion: The incidence of TNBC in our study is similar to other studies. TNBC patientsor reshowed an early majtion  of clinicopathologic fe
molecular features and its
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1.  Background
Breast cancer (BC) is increasingly recognized as a heteroge-
neous disease exhibiting substantial differences with regard
to biological behavior and requiring distinct therapeutic
interventions. Steroid hormone receptors (HR) such as estro-
gen receptor (ER) and progesterone receptor (PR) in concert
with the oncogene ErbB-2/human epidermal growth fac-
tor receptor 2(HER-2) are critical determinants of these BC
subtypes.1–6 Triple-negative breast cancer (TNBC) is charac-
terized by a lack of expression of both ER and PR as well
as HER-2. A recent analysis indicates that TNBC carries a
distinct molecular proﬁle when compared with HR-positive
BC.
A breast cancer classiﬁcation emerged in the sci-
entiﬁc scene based on gene expression proﬁles. The
subgroups (luminal, HER2, normal breast and basal-like;
BLBC) have distinct gene expression patterns and pheno-
typical characteristics. TNBC shares phenotypical features
with basal-like breast cancer, which is in turn the most
aggressive and with worse outcome.7–11 However, the
molecular classiﬁcation of breast cancer has not led to
changes in treatment recommendations and should yet
be considered investigational, as the clinicopathological
entities deﬁned by the use of common immunohisto-
chemistry (IHC) methods still represent the base for such
recommendations.12
In Kuwait, a trend of presentation of breast cancer at ear-
lier age was documented.13 This carries a risk of having more
patients with TNBC (that is known to be more  common at
young ages). Many  reports from different countries across the
world documented different clinicopathological features that
may be different by ethnicity.
2.  Aim
The aim of this study was to determine the incidence of TNBC
in Kuwait. In addition, analysis of the clinical and pathologic
features of TNBC patients in Kuwait as well as the prognosis
of this type of breast cancer was documented. Third, these
ﬁndings were compared with reports representing different
ethnic and demographic populations over the world.
3.  Patients  and  methods
This is a retrospective analysis of the patients who attended
the Kuwait Cancer Control Center (KCCC) for treatment or
follow-up of breast cancer. Based on the Hospital cancer reg-
istry, medical ﬁles of all patients diagnosed with breast cancer
in the period from July 1999 to June 2009 were reviewed.
For all patients, the pathology was reviewed to conﬁrm the
diagnosis and the hormonal receptor and Her-2-neu status.
Pathological diagnosis was based on biopsy from the primary
breast lesion even in the context of cases presented with
metastasis. We  analyzed the clinicopathologic features of 363
triple negative cases which were diagnosed in this period.
The TNM staging was based on pathologic ﬁndings in patients
who  had undergone upfront surgical treatment, while it wasiotherapy 1 9 ( 2 0 1 4 ) 173–181
clinical and radiologic staging in patients who had received
neoadjuvant chemotherapy. The disease-free survival (DFS)
and overall survival (OS) were analyzed by the Kaplan–Meier
method.
ER and PR were assessed using immunohistochemical
staining for quantitative and qualitative assessment. Nega-
tivity was deﬁned as absent IHC stain in all the examined
tissue, i.e. 0%. Her-2-neu scores of 0 and 1 were consid-
ered negative, and a score of 3 was considered positive.14
Score of 2 was considered equivocal and FISH was con-
sidered. Ki67 was considered positive if it was more  than
10%.
Follow up of patients was scheduled to be every 4 months
for the ﬁrst 2 years post-treatment, every 6 months for
the next 3 years then annually. Follow up was by clinical
examination and annual mammography. Follow up duration
was 41.9 months in average (range 1–131 months). Stud-
ies from the USA, Europe, Lebanon, Korea and Japan were
reviewed.23–30
4.  Results
4.1.  Clinical  features
During the period from July 1999 to June 2009, 2980 patients
were documented to have breast cancer in KCCC. Out of them,
363 patients (12.2%) were conﬁrmed to have a triple negative
disease. Patient characteristics are summarized in Table 1. The
mean age was 48 ± 11.7 years for the study population. Median
age at the ﬁrst birth was 23 ± 5.3 years.
4.2.  Pathological  features
Tumor characteristics are summarized in Table 1. Sixty two
percent had T1-2 tumor and the mean tumor volume was 3 cm.
Majority of cases had node negative (42.8%) and 24.1% had N1
disease. N2-3 disease was the rule in 33.1%. Her-2-neu was
negative by IHC staining in 87.6% while FISH was needed to
conﬁrm diagnosis in 45 patients.
Treatment modalities are summarized in Table 2. It should
be mentioned that, in our patient cohort, 51 patients had not
received chemotherapy at all during their treatment course.
4.3.  Pattern  of  failure  Table  3
There were 100 documented recurrences in our study pop-
ulation. The most common site of recurrence was local
recurrence in 10.7% of cases (39% of all recurrences) followed
by bone and lung metastasis that occurred in 7.7% of cases
each (28% of all recurrences each). Liver metastasis was doc-
umented in 5.2%, brain metastasis in 3.8%, and contra-lateral
breast recurrence in 2.2%, (19%, 14%, 8% of all recurrences,
respectively) (Table 3).
4.4.  DFS  and  OS  (Fig.  1)Excluding patients presented with metastatic disease, most of
recurrences happened in the ﬁrst 2–3 years i.e. 81% of recurr-
ences occurred by 2.5 years after treatment. DFS was 76.6%
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nd 74.4% at 3 and 5 years of follow-up, respectively. OS was
3.2% and 81.5% at 3 and 5 years of diagnosis, respectively.
.  Comparison  to  other  reports  from
ifferent  regions  of  the  world
.1.  Epidemiology  and  risk  factors  (Table  4)
here have been no prospective studies speciﬁcally designed
o examine the risk factors associated with speciﬁc molecu-
ar subtypes of breast cancer. However, several retrospective
tudies of large population-based cohorts have attempted
o answer this question. The epidemiological risk fac-
ors for TNBC compared with non-TNBC appear to differ
igniﬁcantly.15–22 Also, it was observed that the epidemiologi-
al and clinicopathologic features of breast cancer vary across
he globe. Based on our results analysis, we can conﬁrm that
ariation also applies to TNBC. We compared our results with
esults from published peer-reviewed results from the USA,
urope, Turkey, Lebanon, Singapore, Korea and Japan.23–30
able 4.or (cumulative and by stage).
5.2.  Prevalence
Overall, the prevalence of TNBC in large unselected breast can-
cer patient cohorts is 11–20%.10,17,18,20,29,31–35 In the compared
studies, Korea seems to have the highest and Lebanon the
lowest27,28 prevalence. In our study, the prevalence of TNBC
was 12.2%.
5.3.  Age  and  reproductive  history
Compared to other breast cancer subtypes, TNBC develops ear-
lier in life, and consequently more  often in pre-menopausal
women.18,29,36
As documented, 63% of patients with triple-negative
tumors were diagnosed before the age of 60 compared with
fewer than half among those with other tumor types.17 High
average age was noticed in a study from MayoClinic (59.7
years).35 In a meta-analysis of 1997 patients by Yang et al.,
the mean age was 56.26
However, many  studies documented 50 years as the mean
age at diagnosis of TNBC.17,23,29,37 In our study, the mean
age was 48 years, younger than the mean age of breast
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Table 1 – Patient and tumor characteristics.
n %
Ethnicity (n = 363)
Caucasian 298 82
Asian 65 18
Age (n = 363)
Bellow 40 88  24
40–60 220 61
Above 60 55 15
Menopausal status (n = 363)
Premenopausal 221 61
Postmenopausal 142 39
Family history of cancer (n = 349)a
Breast 75 21
Other gynecologic 14 4
Others 7 2
History of breast cancer (n = 344)a
Positive 12 3
Negative 332 97
Smoking (n = 298)a
Yes 23 8
No 275 92
Parity (n = 299)a
More than 3 146 49
History of hormone therapy (n = 210)a
Yes 92 44
No 118 56
Breast feeding (n = 208)a
Yes 132 63
No 76 37
Laterality of breast cancer (n = 363)
Right 191 53
Left 169 46
Bilateral 3 1
Localization (n = 363)
UOQ 167 46
Multicentric 38 10
Histological type (n = 363)
IDC 291 80
ILC 13 4
Medullary 35 10
Mucinous and tubular 9 2
Others 12 4
Grade (n = 320)a
I 33 10
II 105 33
III 182 57
T stage (n = 353)a
T1 63 18
T2 156 44
T3 43 12
T4 91 26
N stage (n = 353)a
N0 151 43
N1 85 24
N2 94 27
N3 23 6
Table 1 (Continued)
n %
Metastatic at diagnosis (n = 25)b
Bone 15 60
Lung 10 40
Liver 8 32
Stage (n = 353)a
I 49 14
II 148 42
III 131 37
IV 25 7
Ki67 (n = 198)a
Positive 128 65
Negative 70 35
LVI (n = 315)a
Present 90 29
Absent 225 71
DCIS (n = 301)
Present 77 26
Absent 224 74
a Only available data in cohort cases could be analyzed.
b Some patients were presented with two or more sites of
metastasis.
Table 2 – Treatment modality (n = 363).
N %
Surgery (n = 315)
MRM 201 64
Lumpectomy 114 36
Axillary surgery (n = 309)
Clearance 295 95
Sampling 14 5
Dissected LN (339)
0–9 74 22
10–20 165 49
More than 20 100 29
Chemotherapy (n = 304)
Neoadjuvant 42 14
Adjuvant 194 64
Both 51 17
Palliative 17 5
Type of chemotherapy (n = 304)a
Anthracycline-based 266 87
Taxane-based 144 47
a Some patients received both agents.
Table 3 – Pattern of failure (n = 100).
Site of recurrence % of all cases
Local recurrence 39 10.7
Bone metastasis 28 7.7
Lung metastasis 28 7.7
Liver metastasis 19 5.2
Brain metastasis 14 3.8
Contra-lateral breast cancer 8 2.2
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Table 4 – Patient characteristics in different studies.
Prevalence
(%)
Mean age Premenopausal
(%)
Parity (more
than 3) (%)
OCP (%) Smoking
history (%)
Family history
of cancer (%)
Kuwaita 12.2 48 61 50.2 44 7.7 20
Lebanon26 9.3 52 48 10
Turkey29 10.6 44 70 35
Singapore23 11 53
Korea27 16 45
Japan24 56
Mayo Clinic34 59.7
Bauer et al.16 50 64.6
Dent et al.28 50
Phipps et al.37 57 55 28
Kwan et al.36 34 72 49 20
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ancer in general, independent of phenotype (52 years in
uwait).13 Korea and Turkey have the youngest cohort of
NBC patients (44–45),28,30 while Japan has the oldest (mean
ge was 56 years).25 Fifteen percent were younger than
0 years in the study from Singapore versus 24% in our
tudy.24
Premenopausal status varied from 70% of patients in
urkey,30 48% in Lebanon27 to 61% of TNBC patients in our
tudy. Parity was considered as a characteristic in TNBC
hat deserve reporting in many  studies (Table 5).17,37,38 In
ur study, only 4% were nulliparous (vs. 13% in Yang meta-
nalysis26). This may be related to cultural reasons rather
han a fertility issue. Breast feeding was not documented in
1% of our cohort. However, 37.4% of the documented cases
ack breast feeding similar to that documented by Millikan
t al.20
.4.  History  of  hormone  Intake  and  smoking
orty-four percent gave history of oral contraceptives(OCP) in
ur cohort as compared by 72% in Kwan et al.37 study, 55%
n Phipps et al. study,38 and 35% in the Turkish study.30 Only
.7% of our study cohort gave history of smoking versus 49%
n Kwan et al.37
.5.  Family  history
 positive family history was found in 10% of patients with
NBC in Lebanon compared with 1% of patients with breast
ancer when all phenotypes are included.27,39 In our study,
0% gave that history, similar to that documented by Kwan
t al.37 It was 28% in Phipps et al.38
In Yang meta-analysis,26 having a positive family history
f breast cancer was more  frequent in case of patients with
asal-type tumors compared with patients with ER+/HER2-
r PR+/HER2-tumors (25% vs. 22%) in spite of the absence
f this difference when classiﬁcation was based on IHC only
19% vs. 18%). On the other hand, the family history of
reast cancer was the same between TNBC and non-TNBC
n the Turkish study.30 It seems that genetic inheritance
nd family history is an important risk factor in TNBC in
uwait.5.6.  Tumor  characteristics  Table  5
5.6.1.  Histological  presentation  of  TNBC
More  than 90% of TNBCs exhibit an invasive ductal histol-
ogy (IDC).32,40–44 In current study, 81% were IDC. IDC was
most predominant in Singapore and Japan (93% and 95%,
respectively).24,25 ILC was interestingly documented in 2% of
patients in Singapore24 vs. about 4% in our current study. This
was lately highlighted in an Italian study as 2.3% of their
patients expressed the ILC phenotype.45 This may represent
the pleomorphic subtype of ILC.46 We were very concerned
about these 13 patients and pathology review was done.
Additional characteristics of TNBC are frequent meta-
plastic elements and medullary/atypical medullary
features.40,41,47,48 In our study, 12.9% had metaplastic and/or
medullary carcinomatous features of their tumors.
Triple negative cancers are predominately of high histolog-
ical grade.10,28,29,40,49–53 In our study, similar to many  others,
57% were of high histological grade.29,47,48,54–58 In Singapore,
they documented a higher rate of high grade (77%),24 similar
to a study from Kansas.23
But Japan showed the highest predominance of high grade
tumors (92%).25
5.7.  Ki67
The high frequency of more  aggressive expression proﬁle with
low Bcl-2 but high p53 and Ki67 expression was documented
in many  studies.15,21,40,49–51,53,52 In our study, 65% of exam-
ined specimens showed high mitotic index. Both the Lebanese
study and Dent et al.29 study documented Ki-67 positivity in
50% of patients.27
5.8.  Lymphovascular  invasion  (LVI)
In the study from Mayo Clinic, LVI was less common in
TNBC when compared with HER2+ (18% and 24%, respec-
tively), but both had higher rates than that seen with ER+ (15%,
P = 0.006).35 However, in a Turkish trial, there was no difference
30In our cohort, LVI was documented in 28% of examined
specimens; a much higher rate than that in both studies but
close to that recorded in the Kansas study (33%).23
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Table 5 – Tumor characteristics in TNBC in different studies.
IDC (%) High grade (%) Ki67 (%) LVI (%) Mean tumor
size (cm)
T2 lesion (%) Stages I and II LN + ve (%)
Kuwaita 81 57 65 28 3 43 56 58
Lebanon26 85 63 50 64 50
Turkey29 53 19 29.4
Singapore23 93 77 70
Korea27 53.7 90
Japan24 95 92 43 86.5 34
Mayo Clinic34 88 18
Bauer et al.16
Dent et al.28 63 50 3 54.6
Phipps et al.37
Kwan et al.36 2 48
22Kansas, US 75 33
a Current study.
5.9.  Size  of  tumor
At diagnosis, TNBCs are commonly of larger tumor
size.35,40,49–51,53,52 In our study, the mean tumor size was
3 cm in TNBC group; similar to that in Dent et al.29 study and
larger than other non-TNBC group in the same study (3.0
versus 2.1 cm,  respectively; P < 0.0001). It was smaller (2 cm)
in Tawﬁk et al.23 study. Most of tumors were T2 in Singapore
study (70%).24 In both our study and in Japan, T2 represents
about 43% of cases of TNBC.25
5.10.  Stage
Ghosn et al.27 compared the staging of TNBC as found in the
Lebanese study with the staging of breast cancer of all pheno-
types in Lebanon (stages I and II, 64% versus 75%; stage III, 24%
versus 20%. They concluded that TNBC is more  often locally
advanced at diagnosis.59,60 In our study, stages I and II repre-
sents 56% while stage III represents 37% of TNBC in Kuwait;
which means that TNBC patients are diagnosed at a later stage
in our community. In Japan, 86.5% have stages I and II while
only 10.3% has stage III,25 while it is 90% and 10%, respectively,
in Korea,28 which may result from more  strict and nation-wide
screening systems.
In a series of 1263 women diagnosed with invasive
breast cancer in the Henry Ford Health System, women
with advanced stage (stages III and IV) were 16 times more
likely to have triple-negative tumors than those with early-
stage [odds ratio (OR) 16.4; 95% conﬁdence interval (CI):
7.8–34.2].54
5.11.  Lymph  node  metastasis
The presence of positive lymph nodes in the Lebanese study
was 50%, while it was detected in 58% in our study. With
almost a similar percentage, Dent et al.29 found that the rate
of node positivity was slightly higher in the triple-negative
group compared with the other group (54.6% versus 45.6%,
respectively; P = 0.02). In contrast, non-signiﬁcant difference
was documented by Tawﬁk et al.23 in the study from Kansas
(48 vs. 41%). Interestingly, the ratio was reversed in the Turk-
ish study (29.4 in TNBC vs. 38.5% in non-TNBC)11,30 found it
to be higher in their study (68%) while it was much lower in
Japanese patients (34%).255.12.  Survival
5.12.1.  DFS  and  OS  (Fig.  1)
TNBC accounts for a disproportionate number of BC deaths;
the majority of studies indicate a negative impact of a
TN.10,18,20,21,29,61–65 Patients with TNBC typically have a high
risk of early recurrence that sharply increases in years 1–4 after
diagnosis, and the majority of deaths occur in the ﬁrst 5 years
after treatment.
However, differences between TNBC and non-TNBC
regarding overall survival (OS) wear off at 10 years of follow-
up.66
The risk for late recurrences (i.e. beyond 5 years of diagno-
sis) is decreased by 50% compared with HR-positive disease.67
In other words, for women with triple negative disease, a sub-
stantial number appear to be cured if they remain recurrence
free for the ﬁrst ﬁve years after diagnosis.68
Follow-up of about 200 patients diagnosed with TNBC in
Toronto between 1987 and 1997 showed a peak of recurrence
rate much greater than that of non-TNBC tumors during the
ﬁrst and third years, as well as a higher 5-year mortality
rate.29 This was subsequently conﬁrmed in patients treated
with neoadjuvant therapy at M.D.  Anderson,69 who  showed a
higher 3-year relapse and mortality rates.
In both the Lebanese 27 and US studies (Dent’s 29 and Haffty
et al.70 studies), the peak of recurrence occurred after 6–18
months. In our study, this peak was noticed later; at 30 months
(81% of recurrence).
In the Mayo Clinic Study, local or regional recurrence devel-
oped signiﬁcantly more  often with TN tumors (5.7%) vs. 10.7%
in our study. In the same study, at 5 years after surgery, TN
patients exhibited an overall survival of 85% vs. 81.5 in our
study.35
In Korea, during the median 73.3 months of follow-up,
the 5-year relapse rates among TNBC was 30.1% vs. 26% in
our study, and the 5-year OS rate was 83.1%28 vs. 77% in the
California study.175.12.2.  Aggressiveness
The poor prognosis of high-grade TNBC relates to poor
disease-free interval in the adjuvant setting,29,71 shortened
progression-free survival in the metastatic setting,29,72 and the
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ack of targeted therapy. However, not all TNBCs are associated
ith a poor prognosis.73
.12.3.  Locoregional  recurrence
n a study by Haffty et al.70, they found that the locore-
ional relapse rate for TNBC appears to be identical to that
f other molecular subgroups after conservative surgical man-
gement; however, the TN phenotype appears to be associated
ith a higher rate of distant metastases.
There was no difference between the Lebanese27 and
affty et al.70 studies regarding the sites of metastasis, which
ere, in order of frequency, the lungs, brain, then liver. Dent
nd colleagues 29 found few cases in which local recurrence
receded distant metastases; these, in turn, are more  common
n the viscera and soft tissues than in bone.74,75
Several studies have supported a signiﬁcantly increased
ate of visceral versus bone metastasis57,69 among patients
ith TNBC compared with non-TNBC. In the largest report to
ate, data on 12,858 patients indicate an increased risk for lung
odds ratio (OR) 2.27 and brain (OR 5.32) metastasis as ﬁrst sites
f recurrence and lower risk for bone recurrence (OR 0.23) in
atients with TNBC.32
However, in our cohort, the most common site of recur-
ence was local recurrence in 10.7% of cases (39% of all
ecurrences). This was followed by bone and lung metasta-
is that occurred in 7.7% of cases each (28% of all recurrences
ach). Then comes liver metastasis in 5.2%, brain metastasis
.8%, and contra-lateral breast recurrence in 2.2%, (19%, 14%,
% of all recurrences, respectively).
.12.4.  Central  nervous  system  metastases
atients with TNBC compared with other subtypes report-
dly experience an increased risk of central nervous system
etastases (CM) of 6–46% of those experiencing metastatic
pread of disease.75–77 Similarly, in a single-institution study
mong 3193 patients, a signiﬁcantly elevated risk of CM among
atients with TNBC and HER-2-positive BC compared with
ther phenotypes was reported (HR 4.5 and 4.9 for TNBC and
ER-2+, respectively)76; the risk of CM was particularly pro-
ounced among young patients with node positive disease:
he incidence of CM among patients <50 years of age and node
ositive was 20.0% for TNBC compared with 4.8% for HER-2
ositive. In our study, CM represents the site of metastasis in
4% of the patients experienced metastasis.
Recently, a nomogram has been indicated78 to calculate the
robability for developing cerebral metastasis, particularly for
atients with TNBC, the clinical implications and validation
f which, however, remain unclear.
.  Conclusion
rom the above overview, it seems that TNBC has another
spect of heterogeneity; that is the demographic character-
stics of patients. A step forward toward genetic studies for TNBC is needed as
phenotypic and molecular classiﬁcations lake explanation
for variable responses and prognosis.
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• Regional collaborative studies should be performed in TNBC
to deﬁne underlying molecular unique characteristics that
may affect treatment options in every ethnicity or popula-
tion.
• Another point is the proper evaluation of the TNBC prob-
lem in relation to the whole breast cancer patients in view
of cost-effectiveness; especially in middle and low-income
countries.
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